Econazole

Vulvovaginal Candidiasis Market Pipeline Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Pharmaceutical, Health, Clinical Trials, Treatment, NDA, News, Immunodeficiency, Benzydamine, Clinical trial, La Cambe German war cemetery, VVC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Infection, Patient, Antifungal, II, Econazole, Amphotericin B, Review, Technology, Discovery, Pre-registration house officer, Safety, Partnership, FDA, Acquisition, New Drug Application, Therapy, Pharmaceutical industry, Birth control, Candidiasis, Vagina

The "Vulvovaginal Candidiasis - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vulvovaginal Candidiasis - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The "Vulvovaginal Candidiasis - Pipeline Insight, 2022" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Vulvovaginal Candidiasis pipeline landscape.
  • The assessment part of the report embraces, in depth Vulvovaginal Candidiasis commercial assessment and clinical assessment of the pipeline products under development.
  • This segment of the report provides insights about the different Vulvovaginal Candidiasis drugs segregated based on the following parameters that define the scope of the report, such as:
    There are approx.

Resilia Pharmaceuticals Acquires License to Commercialize Solace™ Eczema Cream in the United States

Retrieved on: 
Monday, October 25, 2021
Cream, COVID-19, Detergent, Atopic dermatitis, Quality of life, PEA, Disease, Organic acid, Dermatology, Amazon, Cholesterol, Ceramide, Journal of the European Academy of Dermatology and Venereology, Patient, Econazole, Itchy, Dermatitis, LLC, OTC, Growth, Board, Skin, Bacteria, Acquisition, Temperature, Allergen, Director, Treatment, Hormone, Pharmaceutical industry, Cosmetics

ATLANTA, Oct. 25, 2021 /PRNewswire/ --Resilia Pharmaceuticals, Inc. announced the signing today of a license agreement with Pelle Ventures, LLC granting Resilia the rights to make, market and sell Solace Eczema Cream, a medical device, as an OTC product in the United States.

Key Points: 
  • ATLANTA, Oct. 25, 2021 /PRNewswire/ --Resilia Pharmaceuticals, Inc. announced the signing today of a license agreement with Pelle Ventures, LLC granting Resilia the rights to make, market and sell Solace Eczema Cream, a medical device, as an OTC product in the United States.
  • "We are delighted to add Solace Cream to the Resilia portfolio of dermatology products, said Harsha Murthy, Executive Chairman of the Board of Directors at Resilia Pharmaceuticals.
  • Resilia is proud to be able to offer patients an effective and safe product like Solace Cream, a product previously available only by prescription.
  • Resilia Pharmaceuticals will begin work immediately to make Solace Cream available on Amazon and plans to expand Amazon promotion.

Global Anti-Fungal Drugs (Azoles, Echinocandins, Polyenes, Allylamines, Others) Markets, 2016-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 8, 2021
Health, Pharmaceutical, Well, Dermatophytosis, Mycosis, Fungal pneumonia, Administration, Route of administration, Polyene, USD, Mucormycosis, Global, CAGR, Ketoconazole, Finger, Investment, Candidiasis, Prevalence, Allylamine, Miconazole, Awareness, Onychomycosis, Market share, Patient, Research, Econazole, Pharmaceutical industry, Fine chemical, Retail

The Global Anti-fungal Drugs Market is expected to reach USD 28484.69 million by 2026, growing at CAGR of 10.39%.

Key Points: 
  • The Global Anti-fungal Drugs Market is expected to reach USD 28484.69 million by 2026, growing at CAGR of 10.39%.
  • An increase in the use of anti-fungal drugs coupled with the rising number of anti-fungal drugs available over-the-counter is expected to boost the market demand.
  • With the surge in popularity of over-the-counter drugs such as ketoconazole, miconazole, econazole, amorolfine, several patients are preferring over-the-counter drugs.
  • The Global Anti-fungal Drugs Market is segmented into drug class, indication, infection type, route of administration, end-user, distribution channel, regional distribution, and company.